Patents by Inventor Ines Herrmann

Ines Herrmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nucleic acids encoding anitbody constructs binding EGFR VIII and CD3
    Patent number: 12152078
    Abstract: The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human EGFRVIII on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.
    Type: Grant
    Filed: September 20, 2021
    Date of Patent: November 26, 2024
    Assignee: AMGEN RESEARCH (MUNICH) GMBH
    Inventors: Tobias Raum, Ines Herrmann, Patrick Hoffmann, Peter Kufer, Markus Muenz, Doris Rau
  • Optimized cross-species specific bispecific single chain antibody contructs
    Patent number: 11661462
    Abstract: The present invention provides to a bispecific single chain antibody construct binding to a target cell surface antigen via a first binding domain and to the T cell surface antigen CD3 via a second binding domain, wherein serum albumin is fused to the C-terminus of the antibody construct. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: May 30, 2023
    Assignee: AMGEN RESEARCH (MUNICH) GMBH
    Inventors: Benno Rattel, Matthias Friedrich, Peter Kufer, Patrick Hoffmann, Tobias Raum, Markus Münz, Ines Herrmann, Ralf Lutterbüse, Elisabeth Nahrwold
  • METHOD FOR TREATING GLIOBLASTOMA OR GLIOMA WITH ANITBODY CONSTRUCTS EGFRVIII AND CD3
    Publication number: 20220064308
    Abstract: The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human EGFRVIII on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.
    Type: Application
    Filed: September 20, 2021
    Publication date: March 3, 2022
    Inventors: Tobias Raum, Ines Herrmann, Patrick Hoffmann, Peter Kufer, Markus Muenz, Doris Rau
  • Method for treating glioblastoma or glioma with antibody constructs for EGFRVIII and CD3
    Patent number: 11155629
    Abstract: The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human EGFRVIII on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.
    Type: Grant
    Filed: November 6, 2019
    Date of Patent: October 26, 2021
    Assignee: AMGEN RESEARCH (MUNICH) GMBH
    Inventors: Tobias Raum, Ines Herrmann, Patrick Hoffmann, Peter Kufer, Markus Muenz, Doris Rau
  • Antibody constructs for EGFRVIII and CD3
    Patent number: 10519241
    Abstract: The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human EGFRVIII on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.
    Type: Grant
    Filed: August 1, 2016
    Date of Patent: December 31, 2019
    Assignee: AMGEN RESEARCH (MUNICH) GMBH
    Inventors: Tobias Raum, Ines Herrmann, Patrick Hoffmann, Peter Kufer, Markus Muenz, Doris Rau
  • OPTIMIZED CROSS-SPECIES SPECIFIC BISPECIFIC SINGLE CHAIN ANTIBODY CONTRUCTS
    Publication number: 20170349668
    Abstract: The present invention provides to a bispecific single chain antibody construct binding to a target cell surface antigen via a first binding domain and to the T cell surface antigen CD3 via a second binding domain, wherein serum albumin is fused to the C-terminus of the antibody construct. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.
    Type: Application
    Filed: July 31, 2015
    Publication date: December 7, 2017
    Inventors: Benno Rattel, Matthias Friedrich, Peter Kufer, Patrick Hoffmann, Tobias Raum, Markus Münz, Ines Herrmann, Ralf Lutterbüse, Elisabeth Nahrwold
  • ANTIBODY CONSTRUCTS FOR EGFRVIII AND CD3
    Publication number: 20170029512
    Abstract: The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human EGFRVIII on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.
    Type: Application
    Filed: August 1, 2016
    Publication date: February 2, 2017
    Inventors: Tobias Raum, Ines Herrmann, Patrick Hoffmann, Peter Kufer, Markus Muenz, Doris Rau